Rucaparib对比化疗治疗携带致病性BRCA1或BRCA2突变复发性卵巢癌(ARIEL4):国际、开放标签、随机3期试验最终结果
ARIEL4试验在12个国家64家医院纳入349例既往接受≥2线化疗的BRCA突变复发性卵巢癌患者,按2:1随机分配至Rucaparib组(233例)或化疗组(116例)。最终分析显示Rucaparib组中位总生存19.4个月(95%CI 15.2-23.6)vs化疗组25.4个月(95%CI 21.4-27.6),HR 1.3(95%CI 1.0-1.7),p=0.047。化疗组80例(69%)交叉接受Rucaparib,未观察到新的安全性信号。
要点
- Rucaparib组中位总生存19.4个月,化疗组25.4个月,HR 1.3(95%CI 1.0-1.7),p=0.047。
- 化疗组116例中80例(69%)交叉接受Rucaparib。
- 3-4级贫血或血红蛋白下降Rucaparib组59例(25%)vs化疗组7例(6%)。
核心结论
- 最终总生存分析显示Rucaparib组中位总生存19.4个月(95%CI 15.2-23.6)vs化疗组25.4个月(95%CI 21.4-27.6),HR 1.3(95%CI 1.0-1.7),p=0.047。
- 作者指出这些数据强调需更好理解PARP抑制剂进展后患者的适宜治疗及晚期卵巢癌中化疗与PARP抑制剂的优化序贯。
研究设计与样本
- 开放标签、随机、对照3期试验,在12个国家64家医院和癌症中心开展。
- 纳入349例年龄≥18岁、携带BRCA1或BRCA2突变、既往接受至少2线化疗的卵巢癌女性患者,按2:1随机分配至Rucaparib组(233例)或化疗组(116例)。
- Rucaparib为口服600 mg每日两次,28天为一周期;化疗组根据铂敏感性状态选择方案:铂耐药或部分铂敏感者接受每周紫杉醇(起始剂量60-80 mg/m2,第1、8、15天给药),完全铂敏感者接受研究者选择的铂类化疗(单药顺铂或卡铂,或铂类双药化疗),21天或28天一周期。
- 主要终点为研究者评估的无进展生存期(既往已报告);总生存为预设次要终点,在意向治疗人群中分析;安全性在所有至少接受一剂研究治疗的患者中评估。
- 数据截止日期为2022年4月10日;研究注册号NCT02855944,入组已完成且研究已关闭。
主要发现
- 2017年3月1日至2020年9月24日期间,349例合格患者被随机分配至Rucaparib组(233例)或化疗组(116例);332例(95%)为白人,17例(5%)为其他种族或种族未知。
- 化疗组116例中80例(69%)交叉接受Rucaparib;中位随访41.2个月(IQR 37.8-44.6)。
- 数据截止时244例(70%)死亡:Rucaparib组233例中167例(72%),化疗组116例中77例(66%)。
- Rucaparib组中位总生存19.4个月(95%CI 15.2-23.6)vs化疗组25.4个月(95%CI 21.4-27.6),HR 1.3(95%CI 1.0-1.7),p=0.047。
- 3-4级贫血或血红蛋白下降Rucaparib组232例中59例(25%)vs化疗组113例中7例(6%);中性粒细胞减少或中性粒细胞计数下降Rucaparib组232例中26例(11%)vs化疗组113例中16例(14%);严重不良事件Rucaparib组232例中66例(28%)vs化疗组113例中14例(12%)。
临床怎么用
- 作者指出这些数据强调需更好理解PARP抑制剂进展后患者的适宜治疗及晚期卵巢癌中化疗与PARP抑制剂的优化序贯。
局限性
- 化疗组116例中80例(69%)交叉接受Rucaparib。
- 作者指出需更好理解PARP抑制剂进展后患者的适宜治疗及化疗与PARP抑制剂的优化序贯。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the ARIEL4 trial of rucaparib versus standard-of-care chemotherapy in patients with relapsed BRCA-mutated ovarian carcinoma, the primary endpoint was met, showing improved investigator-assessed progression-free survival with rucaparib. Here, we present the final overall survival analysis of the trial and other post-progression outcomes. METHODS: This open-label, randomised, controlled phase 3 trial was done at 64 hospitals and cancer centres in 12 countries, including Brazil, Canada, Czech Republic, Hungary, Israel, Italy, Poland, Russia, Spain, Ukraine, the UK, and the USA. Eligible patients were women aged 18 or older with BRCA1 or BRCA2-mutated ovarian carcinoma and had received at least two previous chemotherapy regimens. Patients had to have evaluable disease as per Response Evaluation Criteria in Solid Tumors (RECIST; version 1.1) criteria and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients were randomly assigned (2:1) using an interactive response technology and block randomisation (block size of six) and stratified by progression-free interval after the most recent platinum-containing therapy to receive oral rucaparib (600 mg twice daily administered in 28-day cycles) or chemotherapy on the basis of platinum-sensitivity status. In the chemotherapy group, patients with platinum-resistant disease (progression-free interval ≥1 to <6 months) or partially platinum-sensitive disease (progression-free interval ≥6 to <12 months) received weekly paclitaxel (starting dose 60-80 mg/m2 on days 1, 8, and 15). Patients with fully platinum-sensitive disease (progression-free interval ≥12 months) received the investigator's choice of platinum-based chemotherapy (single-agent cisplatin or carboplatin, or platinum-doublet chemotherapy), in 21-day or 28-day cycles. The primary endpoint (previously reported) was investigator-assessed progression-free survival, assessed in the efficacy population (all randomly assigned patients with deleterious BRCA1 or BRCA2 mutations without reversion mutations) and in the intention-to-treat population (all randomly assigned patients). Overall survival was a prespecified secondary endpoint and was analysed in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of assigned study treatment. The cutoff date was April 10, 2022. This study is registered with ClinicalTrials.gov, NCT02855944; enrolment is complete and the study is closed. FINDINGS: Between March 1, 2017, and Sept 24, 2020, 349 eligible patients were randomly assigned to receive rucaparib (n=233) or chemotherapy (n=116). 332 (95%) of 349 patients were white and 17 (5%) patients were other or of unknown race. In the chemotherapy group, 80 (69%) of 116 patients crossed over to receive rucaparib. Median follow-up was 41·2 months (IQR 37·8-44·6). At data cutoff for this final analysis (April 10, 2022), 244 (70%) of 349 patients had died: 167 (72%) of 233 in the rucaparib group and 77 (66%) of 116 in the rucaparib group. Median overall survival was 19·4 months (95% CI 15·2-23·6) in the rucaparib group versus 25·4 months (21·4-27·6) in the chemotherapy group (hazard ratio 1·3 [95% CI 1·0-1·7], p=0·047). No new safety signals were observed, including during crossover to rucaparib. The most common grade 3-4 adverse events across treatment groups included anaemia or decreased haemoglobin (reported in 59 [25%] of 232 patients in the rucaparib group and seven [6%] of 113 in the chemotherapy group), and neutropenia or decreased neutrophil count (in 26 [11%] of 232 in the rucaparib group and 16 [14%] of 113 patients in the chemotherapy group). Serious adverse events were reported in 66 (28%) of 232 patients in the rucaparib group and 14 (12%) of 113 patients in the chemotherapy group. Ten treatment-related deaths were reported in the rucaparib group, two of which were linked to judged to be related to rucaparib (cardiac disorder and myelodysplastic syndrome), and one death related to treatment was reported in the chemotherapy group, with no specific cause linked to the treatment. INTERPRETATION: These data highlight the need for a better understanding of the most appropriate treatment for patients who have progressed on a poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitor, and the optimal sequencing of chemotherapy and PARP inhibitors in advanced ovarian cancer. FUNDING: Clovis Oncology.
引用
- Oza AM, Lisyanskaya A, Fedenko A, et al. Rucaparib versus chemotherapy for treatment of relapsed ovarian cancer with deleterious BRCA1 or BRCA2 mutation (ARIEL4): final results of an international, open-label, randomised, phase 3 trial. Lancet Oncol. 2025. PMID: 39914419. doi:10.1016/S1470-2045(24)00674-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。